Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines

Keiichiro Nakamura, Yasutomo Nasu, Atsushi Hongo, Tamaki Matsuo, Junichi Kodama, Shin Ebara, Atsushi Nagai, Fernando Abrzua, Hiromi Kumon, Yuji Hiramatsu

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


In light of the poor prognosis for ovarian cancer patients, the research continues for innovative and efficacious treatment modalities. Along with surgical and chemotherapeutic regimens, gene therapy has emerged as one of the leading contenders in the treatment armamentarium. Hepsin is a type II transmembrane serine protease originally identified in the human liver as a cDNA clone. However, the biological function of Hepsin expression remains unclear. Apoptotic cell was increasingly common among higher proportions of Hepsin transfectants. We discovered that first-time stable transfectants of Hepsin significantly inhibited cell growth in the monolayer, anchorage-independent cell growth in the soft agar in vitro, and tumorigenicity in vivo in ovarian cancer cell lines. These results demonstrated that Hepsin has a potential therapeutic effect that inhibits through up-regulation of p53-dependent apoptosis and caspase-3, -6, and -7 activations. Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment.

Original languageEnglish
Pages (from-to)393-398
Number of pages6
JournalInternational journal of oncology
Issue number2
Publication statusPublished - Feb 2006


  • Caspase
  • Hepsin
  • Ovarian cancer
  • p53-dependent apoptotic pathway

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines'. Together they form a unique fingerprint.

Cite this